Dataset Information

The Struggling Infectious Diseases Fellow: Remediation Challenges and Opportunities.

ABSTRACT: Remediation of struggling learners is a challenge faced by all educators. In recognition of this reality, and in light of contemporary challenges facing infectious diseases (ID) fellowship program directors, the Infectious Diseases Society of America Training Program Directors' Committee focused the 2018 National Fellowship Program Directors' Meeting at IDWeek on "Remediation of the Struggling Fellow." Small group discussions addressed 7 core topics, including feedback and evaluations, performance management and remediation, knowledge deficits, fellow well-being, efficiency and time management, teaching skills, and career development. This manuscript synthesizes those discussions around a competency-based framework to provide program directors and other educators with a roadmap for addressing common contemporary remediation challenges.

SUBMITTER: Melia MT

PROVIDER: S-EPMC7061231 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

The Struggling Infectious Diseases Fellow: Remediation Challenges and Opportunities.

Melia Michael T MT Paez Armando A Reid Gail G Chirch Lisa M LM Luther Vera P VP Blackburn Brian G BG Perez Federico F Abdoler Emily E Kaul Daniel R DR Rehm Susan S Harik Nada N Barsoumian Alice A Person Anna K AK Yun Heather H Beckham J David JD Boruchoff Susan S Cariello Paloma F PF Cutrell James B JB Graber Christopher J CJ Lee Dong Heun DH Maziarz Eileen E Paras Molly L ML Razonable Raymund R RR Ressner Roseanne R Chen Anne A Chow Brian B Escota Gerome G Herc Erica E Johnson Andrew A Maves Ryan C RC Nnedu Obinna O Clauss Heather H Kulkarni Prathit P Pottinger Paul S PS Serpa Jose A JA Bhowmick Tanaya T Bittner Marvin M Wooten Darcy D Casanas Beata B Shnekendorf Rachel R Blumberg Emily A EA

Open forum infectious diseases 20200218 3

Remediation of struggling learners is a challenge faced by all educators. In recognition of this reality, and in light of contemporary challenges facing infectious diseases (ID) fellowship program directors, the Infectious Diseases Society of America Training Program Directors' Committee focused the 2018 National Fellowship Program Directors' Meeting at IDWeek on "Remediation of the Struggling Fellow." Small group discussions addressed 7 core topics, including feedback and evaluations, performan ...[more]

PMID: 32166097

Similar Datasets

Project description:To improve quality of life and prevent long-term risks in patients with inflammatory bowel diseases (IBDs: Crohn's disease, ulcerative colitis), it is essential to suppress inflammatory activity adequately. However, corticosteroids are only suitable for therapy of acute flares and the evidence for positive effects of immunosuppressive substances like azathioprine or 6-mercapropurine is mainly limited to maintenance of remission. In addition, only subgroups of patients benefit from biologicals targeting tumour necrosis factor ? or ?4?7 integrins. In summary, until now the disease activity is not sufficiently controlled in a relevant fraction of the patients with IBD. Thus, there is an urge for the development of new substances in the therapy of ulcerative colitis and Crohn's disease. Fortunately, new oral and parenteral substances are in the pipeline. This review will focus on oral substances, which have already passed phase II studies successfully at this stage. In this article, we summarize data regarding AJM300, phosphatidylcholine (LT-02), mongersen, ozanimod, filgotinib and tofacitinib. AJM300 and ozanimod were tested in patients with ulcerative colitis and target lymphocyte trafficking through inhibition of the ? subunit of integrin, respectively binding to the sphingosine-1-phosphate receptor (subtypes 1 and 5) on lymphocytes. Mongersen was utilized in patients with Crohn's disease and accelerates the degradation of SMAD7 mRNA, which consequently strengthens the mainly anti-inflammatory signalling pathway of transforming growth factor ?1. Various Janus kinase (JAK) inhibitors were developed, which inhibit the intracellular signalling pathway of cytokines. For example, the JAK1 blocker filgotinib was tested in Crohn's disease, whereas the JAK1/3 inhibitor tofacitinib was tested in clinical trials for both Crohn's disease and ulcerative colitis. A different therapeutic approach is the substitution of phosphatidylcholine (LT-02), which might recover the colonic mucus. Taken together, clinical trials with these new agents have opened avenues for further clinical studies and it can be expected that at least some of these agents will be finally approved for clinical therapy.

Dataset Information

The Struggling Infectious Diseases Fellow: Remediation Challenges and Opportunities.

Publications

The Struggling Infectious Diseases Fellow: Remediation Challenges and Opportunities.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure